Not yet recruiting
Multi-center Study of Three-Dimensional Transesophageal Echocardiography in Patients With Secondary Mitral Regurgitation
NCT07918937· First Hospital of China Medical University· Source
Contact: Chang Zhou (principal investigator)
Not yet recruiting
Early Lumbar Drainage for Intraventricular Hemorrhage
NCT07625449· Second Affiliated Hospital of Nanchang University· Source
Contact: Yichang Central People's Hospital
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source
Contact: Qinhan Chen
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
NCT07747857· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Weimin Zhao, Master
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Lin Teng
Recruiting
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
NCT07741448· Phase 2· Zhiquan Hu· Source
Contact: Xiaobo Chen, M.D.
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Contact: Qing Yan
Active, not recruiting
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
NCT07662122· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xiaoqiang Hou, Master
Recruiting
Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases
NCT07595068· Renmin Hospital of Wuhan University· Source
Contact: Zhuli Guo, MD
Recruiting
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Fanjun Zeng, Master
Recruiting
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986· Phase 2· Hangzhou Sumgen Biotech Co., Ltd.· Source
Contact: Xiaoqiang Hou, Master
Not yet recruiting
Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)
NCT07469293· Phase 3· Southwest Hospital, China· Source
Contact: Zhou Jinghua
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Xiong Xiao Qi
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Xiaoqi Xiong
Not yet recruiting
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE)
NCT07274137· Phase 3· MindRank AI Ltd· Source
Contact: Jun Zeng
Active, not recruiting
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
NCT07230119· Phase 3· Beijing QL Biopharmaceutical Co.,Ltd· Source
Recruiting
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
NCT07284134· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Contact: Qiao Huang, Doctor
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Xiaoqiang Hou
Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
NCT07208097· Tongji Hospital· Source
Contact: Xia Kailai
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
NCT07187687· Xuanwu Hospital, Beijing· Source
Contact: chunlei tian
Recruiting
Burst Stimulation for Paroxysmal Atrial Fibrillation
NCT07281898· Zhibing Lu· Source
Contact: Zhuli Guo
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264· Phase 2· Dizal Pharmaceuticals· Source
Contact: Cai
Recruiting
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07288554· Phase 1· Bambusa Therapeutics· Source
Contact: Xiaoqi Xiong
Not yet recruiting
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Fanjun Zeng, Master
Recruiting
Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above
NCT07152639· Phase 3· Chengdu CoenBiotech Co., Ltd· Source
Contact: Xi Wei
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source
Contact: Yaowei Bai
Recruiting
A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT07292714· Phase 2· Mabwell (Shanghai) Bioscience Co., Ltd.· Source
Contact: Yongchang Sun, Doctor
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Xiaolin Zhou
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548· Phase 1/2· BioNTech SE· Source
Not yet recruiting
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861· Phase 2· Shanghai Huilun Pharmaceutical Co., Ltd.· Source
Contact: Xinyu Song
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265· Phase 3· Beletalent (Zhuhai) Pharmaceutical Co., Ltd· Source
Contact: Yan Zhang
Recruiting
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
NCT07128186· Tongji Hospital· Source
Contact: Zhaoyang Zeng
Not yet recruiting
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
NCT06922903· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Not yet recruiting
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
NCT06922929· Phase 3· Yunhe Pharmaceutical (Tianjin) Co., Ltd· Source
Contact: Dong Yuan
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688· Phase 3· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source
Contact: Yuyan Tan, M.D., Ph.D.
Active, not recruiting
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT06707883· Phase 2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006· Phase 3· Shanghai Henlius Biotech· Source
Contact: Ying Li
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Boehringer Ingelheim· Source
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT)
NCT06559241· Phase 3· Capital Medical University· Source
Contact: Huajun Zhou
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531· JIANGSU SHENMING Medical Technology CO., Ltd· Source
Contact: Cui Chen, chief physician
Recruiting
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT06431490· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Cui Chen, Master
Active, not recruiting
Efficacy and Safety of Colchicine After PCI
NCT06472908· Phase 3· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Source
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source
Recruiting
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
NCT06378138· Phase 2/3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Huili Cai
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Xinhua Xu (principal investigator)
Active, not recruiting
To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer
NCT05365178· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Active, not recruiting
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Showing 50 of 51.